These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 12901232

  • 81. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
    Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M.
    Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
    [Abstract] [Full Text] [Related]

  • 82. Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation.
    Lu JG, Sun YN, Wang C, Jin DJ, Liu M.
    Eur Arch Otorhinolaryngol; 2009 Jan; 266(1):89-96. PubMed ID: 18427826
    [Abstract] [Full Text] [Related]

  • 83.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 84.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 85. Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.
    Dittmar T, Heyder C, Gloria-Maercker E, Hatzmann W, Zänker KS.
    Clin Exp Metastasis; 2008 Jan; 25(1):11-32. PubMed ID: 17828597
    [Abstract] [Full Text] [Related]

  • 86.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 87. [Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies].
    Rass K, Tadler D, Tilgen W.
    Hautarzt; 2006 Sep; 57(9):773-84. PubMed ID: 16924435
    [Abstract] [Full Text] [Related]

  • 88. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.
    Ye Y, Bloch S, Xu B, Achilefu S.
    J Med Chem; 2006 Apr 06; 49(7):2268-75. PubMed ID: 16570923
    [Abstract] [Full Text] [Related]

  • 89.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 90. Improving outcomes in advanced malignant melanoma: update on systemic therapy.
    Danson S, Lorigan P.
    Drugs; 2005 Apr 06; 65(6):733-43. PubMed ID: 15819587
    [Abstract] [Full Text] [Related]

  • 91. Integrin alpha v beta 3-targeted imaging of lung cancer.
    Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, Bremner R, Bading JR, Conti PS.
    Neoplasia; 2005 Mar 06; 7(3):271-9. PubMed ID: 15799827
    [Abstract] [Full Text] [Related]

  • 92.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 93.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 94. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.
    Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C.
    J Cancer Res Clin Oncol; 2005 Jan 06; 131(1):41-8. PubMed ID: 15565459
    [Abstract] [Full Text] [Related]

  • 95.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 96. Alpha v integrin inhibitors and cancer therapy.
    Tucker GC.
    Curr Opin Investig Drugs; 2003 Jun 06; 4(6):722-31. PubMed ID: 12901232
    [Abstract] [Full Text] [Related]

  • 97. Integrin targeted drug and gene delivery.
    Wang Z, Chui WK, Ho PC.
    Expert Opin Drug Deliv; 2010 Feb 06; 7(2):159-71. PubMed ID: 20095940
    [Abstract] [Full Text] [Related]

  • 98.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 99. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD, Scharf O, Schoenfeldt M.
    Oncology (Williston Park); 2004 Dec 06; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract] [Full Text] [Related]

  • 100.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.